U.S. Markets open in 2 hrs 52 mins

Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will provide a corporate update at the Bank of America Merrill Lynch 2019 Healthcare Conference, being held in Las Vegas, NV, from May 14-16, 2019.

Presentation Details

Date: Tuesday, May 14, 2019
Time: 8:00 PM Eastern Time / 5:00 PM Pacific Time
Location: Las Vegas, NV - Encore Hotel
   

The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company’s NDA. For more information, visit www.zogenix.com.

CONTACT:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
media@zogenix.com

Media
Rachel Lipsitz
Public Relations, Syneos Health
+1 (858) 449 9575 | rachel.lipsitz@syneoshealth.com  

Investors
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com